Compare Abeona Therapeutics Inc (ABEO) vs Prudential PLC (PUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Prudential PLC — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Prudential PLC trades at $27.33 (market cap $33.92B). The key difference: Prudential PLC is far larger — about 90.9× Abeona Therapeutics Inc's market cap, and Prudential PLC pays a 1.92% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PUK | |
|---|---|---|
Market Cap | $373.32M | $33.92B |
Sector | Health | Financials |
52-Week High | $7.23 | $33.61 |
52-Week Low | $4.17 | $24.65 |
Enterprise Value | $228.22M | $35.36B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Prudential PLC (PUK) trades at $27.65, up 0.33% today, with a bullish technical outlook and strong fundamentals including a 14.52% net income margin and 21.15% ROE. Recent earnings beat expectations in Q2 and Q4 2025, though Q4 2024 missed. The company shows robust cash flow growth, with operating cash flow reaching $3.61B in 2024, and strategic moves like the Bharti Life Insurance acquisition signal expansion intent. Analyst consensus is mixed but leans positive with 50% buy ratings.
The stock presents a value opportunity with a low P/E of 9.16, but faces risks from regulatory challenges in Japan and market volatility. Upside potential is supported by earnings growth and institutional confidence, though investors should monitor Japan's sales suspension impact and competitive pressures in insurance markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
